The FDA has approved the fast-acting insulin Apidra (insulin glulisine) for use in children four years and older who have type 1 diabetes.
Apidra, manufactured by sanofi-aventis, is a rapid-acting insulin that can be administered via an insulin infusion pump, vial and syringe, insulin pen, or intravenously. Users typically inject it within 15 minutes before or 20 minutes after the start of a meal.